# A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

> **NCT04564456** · PHASE1 · COMPLETED · sponsor: **Respirent Pharmaceuticals Co Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent
- **DRUG:** ADVAIR DISKUS® 500/50

## Key facts

- **NCT ID:** NCT04564456
- **Lead sponsor:** Respirent Pharmaceuticals Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-22
- **Primary completion:** 2020-10-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564456, "A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04564456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*